Scientists test Dual-Attack on Tough-to-Treat lung cancers
NCT ID NCT05879978
Summary
This early-stage study is testing a new combination of two immunotherapy drugs, obrixtamig and ezabenlimab, for adults with advanced small cell lung cancer or similar neuroendocrine tumors that have stopped responding to standard treatments. The main goal is to find the highest dose of obrixtamig that can be safely given alongside ezabenlimab. Participants receive the drugs by IV infusion for up to three years if they are benefiting and tolerating the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CTR François Baclesse
Caen, 14000, France
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
HOP Louis Pradel
Bron, 69677, France
-
INS Claudius Regaud IUCT-Oncopole
Toulouse, 31059, France
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
Technische Universität Dresden
Dresden, 01307, Germany
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
Universitätsklinikum Frankfurt
Frankfurt, 60590, Germany
Conditions
Explore the condition pages connected to this study.